Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients.
PARP inhibitors
androgen receptor (AR) antagonist
combined treatment
radiosensitizing agents
salvage prostate bed radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
09
2021
accepted:
30
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Although salvage prostate bed radiotherapy is highly effective in biochemically-relapsing prostate cancer patients following prostatectomy, relapses remain frequent and improvements are needed. Randomized phase 3 trials have shown the benefit of adding androgen-depriving therapy to irradiation, but not all patients benefit from this combination. Preclinical studies have shown that novel agents targeting the androgen receptor, DNA repair, PI3K/AKT/mTOR pathways, or the hypoxic microenvironment may help increase the response to prostate bed irradiation while minimizing potential side effects. This perspective review focuses on the most relevant molecules that may have an impact when combined with salvage radiotherapy, and underlines the strategies that need to be developed to increase the efficacy of salvage post-prostatectomy radiotherapy in prostate cancer patients.
Identifiants
pubmed: 35004302
doi: 10.3389/fonc.2021.780507
pmc: PMC8739777
doi:
Types de publication
Journal Article
Langues
eng
Pagination
780507Informations de copyright
Copyright © 2021 Cailleteau, Sargos, Saad, Latorzeff and Supiot.
Déclaration de conflit d'intérêts
SS: coordinating investigator of the GETUG 33 CARLHA 2 study funded by Janssen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):846-53
pubmed: 12788194
Oncotarget. 2018 Apr 24;9(31):22147-22157
pubmed: 29774129
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Radiother Oncol. 2013 Jan;106(1):138-46
pubmed: 23321494
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):477-83
pubmed: 19733014
Eur Urol. 2021 Oct;80(4):405-414
pubmed: 34247896
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
Nat Commun. 2017 Jan 09;8:13671
pubmed: 28067867
Front Oncol. 2016 Feb 16;6:24
pubmed: 26909338
Nat Rev Clin Oncol. 2011 Feb;8(2):107-13
pubmed: 21178999
Front Oncol. 2021 May 07;11:675311
pubmed: 34026653
Lancet Oncol. 2021 Aug;22(8):e348-e357
pubmed: 34339655
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Prostate Cancer Prostatic Dis. 2016 Mar;19(1):100-6
pubmed: 26754260
Nat Med. 2019 Oct;25(10):1615-1626
pubmed: 31591588
J Clin Oncol. 2007 Jun 1;25(16):2225-9
pubmed: 17538167
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
JAMA Oncol. 2020 May 1;6(5):735-743
pubmed: 32215583
Eur Urol Oncol. 2021 Dec;4(6):948-954
pubmed: 32063492
Lancet Oncol. 2019 Dec;20(12):1740-1749
pubmed: 31629656
Prostate. 2018 Jan;78(1):64-75
pubmed: 29134684
Oncotarget. 2017 Jul 7;8(40):69105-69124
pubmed: 28978184
Cancer Res. 2015 Nov 15;75(22):4688-96
pubmed: 26432404
Oncotarget. 2018 Jan 13;9(11):10005-10015
pubmed: 29515786
Radiat Oncol. 2011 Apr 15;6:39
pubmed: 21496273
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1061-1067
pubmed: 30557672
Crit Rev Oncol Hematol. 2015 Dec;96(3):507-17
pubmed: 26253360
Mol Cancer Ther. 2008 Jul;7(7):1772-81
pubmed: 18644989
Adv Radiat Oncol. 2015 Dec 09;1(1):59-66
pubmed: 28799570
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):355-361
pubmed: 27986349
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Radiat Oncol. 2021 Feb 10;16(1):32
pubmed: 33568190
EBioMedicine. 2018 May;31:182-189
pubmed: 29729848
Radiother Oncol. 2018 Feb;126(2):244-248
pubmed: 29132644
Cell. 2018 May 3;173(4):1003-1013.e15
pubmed: 29681457
Cancer Radiother. 2019 Jun;23(3):194-200
pubmed: 31088725
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Eur Urol Focus. 2020 Mar 15;6(2):231-234
pubmed: 31248850
N Engl J Med. 2017 Feb 2;376(5):417-428
pubmed: 28146658
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):84-91
pubmed: 30170099
JAMA Oncol. 2021 Apr 1;7(4):544-552
pubmed: 33570548
Cancer Res. 2007 Jul 1;67(13):6022-5
pubmed: 17616657
Nature. 2009 Feb 12;457(7231):E1; discussion E2-3
pubmed: 19212347
J Thorac Oncol. 2009 Jun;4(6):761-7
pubmed: 19404218
Cancer Discov. 2013 Nov;3(11):1254-71
pubmed: 24027197
Eur Urol. 2013 Apr;63(4):709-16
pubmed: 23287698
Urol Oncol. 2014 Apr;32(3):372-3
pubmed: 24679462
BMC Urol. 2021 Jul 1;21(1):96
pubmed: 34210300
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Lancet Oncol. 2014 Dec;15(13):1521-1532
pubmed: 25456371
Oncotarget. 2014 Nov 30;5(22):11081-90
pubmed: 25415046
Lancet. 2021 Jul 10;398(10295):131-142
pubmed: 34246347
Cell. 2009 Dec 11;139(6):1069-83
pubmed: 19962179
Lancet Oncol. 2008 Apr;9(4):342-51
pubmed: 18343725
Br J Cancer. 2009 Mar 24;100(6):932-40
pubmed: 19240717
Nat Genet. 2010 Aug;42(8):668-75
pubmed: 20601956